


# Selected Innovative Medicines in Development as of January 22, 2025



# Oncology (1 of 2)

## **RYBREVANT / LAZCLUZE**

Non Small Cell Lung Cancer (MARIPOSA)

## **DARZALEX (daratumumab)**

Frontline multiple myeloma transplant eligible (PERSEUS)

## **RYBREVANT (amivantamab)**

Subcutaneous (PALOMA-3)

## **TECVAYLI (teclistamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

## **TECVAYLI (teclistamab)**

Multiple Myeloma 1-3PLs (MajesTEC-3)

## **TALVEY (talquetamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)

## **TAR-200**

High Risk Non Muscle Invasive Bladder Cancer BGC Experienced (SunRISe-5)

## **ERLEADA (apalutamide)**

Localized Prostate Cancer (ATLAS)

## **IMBRUVICA (ibrutinib)**

Frontline Mantle Cell Lymphoma (Triangle)

## **DARZALEX (daratumumab)**

Frontline multiple myeloma transplant ineligible (CEPHEUS)

## **RYBREVANT (amivantamab)**

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

## **TECVAYLI (teclistamab)**

TIE NDMM in combination with DR (MajesTEC-7)

## **TAR-210 (RIS/erdafitinib)**

Intravesical Delivery System for Localized Bladder Cancer (MoonRISe-1)

## **TALVEY (talquetamab)**

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

## **TAR-200 (RIS/gemcitabine plus cetrelimab)**

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

## **CARVYKTI (Ciltacabtagene autoleucel)**

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

## **IMBRUVICA (ibrutinib)**

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

## **DARZALEX (daratumumab)**

Smoldering Multiple Myeloma (AQUILA)

## **TALVEY (talquetamab)**

TIE NDMM in combination with DR (MajesTEC-7)

## **TECVAYLI (teclistamab)**

TE NDMM maintenance (MajesTEC-4)

## **TALVEY + TECVAYLI**

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)

## **AKEEGA (niraparib/abiraterone)**

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

## **ERLEADA (apalutamide)**

High Risk Prostate Cancer (PROTEUS)

## **CARVYKTI (Ciltacabtagene autoleucel)**

Frontline Multiple Myeloma TNI (CARTITUDE-5)

## Oncology (2 of 2)

---

### **RYBREVANT (amivantamab)**

Colorectal Cancer (ORIGAMI-2)

### **JNJ-0683 (ARX788)**

Breast Cancer

### **VAC85135**

Hematological Malignancies

### **JNJ-4496**

Hematological Malignancies

### **JNJ-9968**

Hematological Malignancies

### **JNJ-9401**

Prostate Cancer

### **JNJ-2421**

Solid Tumor Targeted Therapy

### **JNJ-4681**

Hematological Malignancies

### **TALVEY + TECVAYLI**

Relapsed Refractory Multiple Myeloma (RedirectT-1)

### **JNJ-1900**

Lung Cancer

### **JNJ-2638**

Gastrointestinal Cancer

### **JNJ-9530**

Hematological Malignancies

### **JNJ-0387**

Solid Tumors

### **JNJ-8543**

Hematological Malignancies

### **JNJ-8343**

Prostate Cancer

### **JNJ-0631 (ARX305)**

Renal Cancer

### **TAR-200 (RIS/gemcitabine plus cetrelimab)**

Non Muscle Invasive Bladder Cancer (SunRISe-1)

### **bleximenib**

Relapsed Refractory Acute Myeloid Leukemia (ALE1001)

### **JNJ-8177 (ARX517)**

Prostate Cancer

### **JNJ-8377**

Lymphoma

### **JNJ-1493**

Hematological Malignancies

### **JNJ-5322**

Multiple Myeloma

### **JNJ-6420**

Prostate Cancer

# Immunology (1 of 2)

**TREMFYA (guselkumab)**  
Pediatric Juvenile Psoriatic Arthritis

**TREMFYA (guselkumab)**  
Ulcerative Colitis (QUASAR)

**STELARA (ustekinumab)**  
Pediatric Juvenile Psoriatic Arthritis

**TREMFYA (guselkumab)**  
Pediatric Ulcerative Colitis (QUASAR JR)

**STELARA (ustekinumab)**  
Pediatric Ulcerative Colitis (UNIFY JR)

**nipocalimab**  
Warm Autoimmune Hemolytic Anemia (ENERGY)

**nipocalimab**  
Sjogren's Disease

**icotrokinra**  
Ulcerative Colitis

**TREMFYA (guselkumab)**  
Ulcerative Colitis Subcutaneous Induction (ASTRO)

**TREMFYA (guselkumab)**  
Pediatric Psoriasis (PROTOSTAR)

**STELARA (ustekinumab)**  
Pediatric Crohn's Disease (UNITI JR)

**TREMFYA (guselkumab)**  
Pediatric Crohn's Disease (MACARONI-23)

**nipocalimab**  
Fetal and Neonatal Alloimmune Thrombocytopenia (FREEZIA)

**icotrokinra**  
Psoriasis (ICONIC)

**nipocalimab**  
Systemic Lupus Erythematosus

**JNJ-4804 Co-antibody Therapeutic**  
Crohn's Disease

**TREMFYA (guselkumab)**  
Crohn's Disease Subcutaneous Induction (GRAVITI)

**TREMFYA (guselkumab)**  
Crohn's Disease (GALAXI)

**SIMPONI (golimumab)**  
Pediatric Ulcerative Colitis (PURSUIT 2)

**TREMFYA (guselkumab)**  
Psoriatic Arthritis Structural Damage (APEX)

**nipocalimab**  
Hemolytic Disease of the Fetus and Newborn (AZALEA)

**nipocalimab**  
Idiopathic Inflammatory Myopathy

**nipocalimab Combination Therapy**  
Rheumatoid Arthritis

**JNJ-4804 Co-antibody Therapeutic**  
Psoriatic Arthritis

# Immunology (2 of 2)

---

**JNJ-4804 Co-antibody Therapeutic**

Ulcerative Colitis

**JNJ-5108**

Immunological Diseases

**JNJ-7528**

Atopic Dermatitis

**JNJ-5939 (NM26)**

Atopic Dermatitis

# Neuroscience

---

## **nipocalimab**

Generalized Myasthenia Gravis (Vivacity MG3)

## **RPGR Gene Therapy**

Retinitis Pigmentosa (LUMEOS)

## **posdinemab**

Alzheimer's Disease (AUTONOMY)

## **JNJ-5120**

Major Depressive Disorder

## **SPRAVATO (esketamine)**

Treatment Resistant Depression monotherapy (TRD4005)

## **nipocalimab**

Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

## **nipocalimab**

Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

## **JNJ-1887 sCD59**

Geographic Atrophy

## **seltorexant**

Adjunctive treatment for major depressive disorder with insomnia symptoms (OARS)

## **aticaprant**

Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura)

## **SPRAVATO (esketamine)**

Major Depressive Disorder with Suicidal Ideation Pediatrics

## **JNJ-2056 (tau active immunotherapy) \***

Alzheimer's Disease (RETAIN)

## Select Other Areas

---

**CABENUVA**  
HIV Adolescents

**SIRTURO**  
Leprosy

**milvexian (Factor Xla)**  
Atrial Fibrillation

**SIRTURO**  
Tuberculosis Long Acting

**OPSUMIT (macitentan)**  
Pediatric Pulmonary Arterial Hypertension (TOMORROW)

**macitentan**  
Pulmonary Arterial Hypertension 75mg (UNISUS)

**milvexian (Factor Xla)**  
Acute Coronary Syndrome

**prostacyclin receptor agonist**  
Pulmonary Arterial Hypertension

**UPTRAVI (selexipag)**  
Pediatric Pulmonary Arterial Hypertension (SALTO)

**VAC52416**  
Multivalent ExPEC Vaccine

**milvexian (Factor Xla)**  
Secondary Stroke Prevention

---

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 22, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. \*AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; X-Linked Retinitis Pigmentosa (AAV-RPGR): MeiraGTx; JNJ-1887: Hemera Biosciences; Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; ExPEC: Sanofi; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKT: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuh an Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CART-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); JNJ-1459: X-CHEM